Low Humoral Immune Response and Ineffective Clearance of SARS-Cov-2 in a COVID-19 Patient With CLL During a 69-Day Follow-Up
Conclusion: In CLL, a neoplastic antigen-specific B-cell clone proliferates, and the progeny cells accumulate and outgrow other B cells, leading to immune deficiency. Considering the low humoral immune response and ineffective clearance of SARS-Cov-2 in CLL patients, the follow-up and home quarantine period should be extended. We need further studies to clarify suspending or continuing CLL therapy during COVID infection. For those patients who are prone to progression to severe disease, administering humoral immunity therapies can help to prevent disease progression and quickly meet the cure criteria.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Antiviral Therapy | Cancer & Oncology | China Health | Chronic Leukemia | Chronic Lymphocytic Leukemia | Coronavirus | COVID-19 | Hematology | Laboratory Medicine | Leukemia | Outbreaks | Papanicolaou (Pap) Smear | PET Scan | Pneumonia | Respiratory Medicine | SARS | Study